Category - News

Developments

IntelGenx begins patient dosing in VersaFilm Phase 2a AD study

IntelGenx (TSXV:IGX; OTCQX:IGXT) began patient dosing in the Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). The True North Clinical Research site in Kentville, Nova...

November 27, 2018

Developments

Leerink starts coverage of 10 biopharma and generic stocks

Leerink initiated coverage of 10 biopharma and generic stocks, saying the sector is rich with companies developing drugs with the aim to treat and/or definitively cure conditions ranging from rare, severe inherited...

November 27, 2018

Developments

Interface Biologics preparing Phase 2 intravitreal implant study after FDA meeting

Following a successful pre-IND meeting with FDA, closely-held Interface Biologics (IBI) is preparing to initiate a Phase 2 trial with its dexamethasone intravitreal implantin patients with diabetic macular edema. The...

November 27, 2018

Markets

JP Morgan starts Orchard Therapeutics at OW; PT $25

JP Morgan launched coverage of Orchard Therapeutics (NASDAQ:ORTX) with an “overweight” rating and December 2019 price target of $25. The stock closed at $16.75 on Nov. 22. Analyst Anupam Rama writes that Orchard, in a...

November 26, 2018

Developments

Canopy Growth completes acquisition of ebbu assets

Canopy Growth (TSX:WEED; NYSE:CGC) completed the acquisition of the assets of ebbu, a leader in hemp research and innovation, for $25-million and 6,221,210 common shares. Under the accord, Canopy would pay up to an...

November 26, 2018

Markets

JP Morgan starts Audentes Therapeutics at OW; PT $35

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...

November 26, 2018

Developments

Lobo Genetics going public in RTO of Cassowary Capital

Closely-held Lobo Genetics entered into a non-binding letter of intent with Cassowary Capital (TSXV:BIRD) that will result in a reverse takeover of Cassowary by Lobo. Cassowary is a capital pool company on the TSX...

November 22, 2018

Markets

BTIG ups Helius Medical to buy; PT $14

BTIG upgraded Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) to “buy” from “neutral,” with a $14 price target, after the company closed a $17.5-million stock offering. The stock closed at $8 on Nov. 19. Analyst Dr...

November 21, 2018

Markets

HCW assumes coverage of Caladrius Biosciences at buy; PT $18.50

H.C. Wainwright analyst Joseph Pantginis assumed coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $18.50. The stock closed at $4.52 on Nov. 19. Caladrius is developing two...

November 20, 2018

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX: IGXT) 505(b)(2) NDA resubmission of RIZAPORT oral soluble film 10 mg for the treatment of acute migraines. The FDA also assigned a Prescription Drug User Fee Act (PDUFA)...

November 20, 2018

Category - News

Subscribe